Pfizer anticipates funding the transaction through a combination of existing cash and new debt and expects the transaction to result in $800 million in annual cost savings by 2018, according to a news release.
In a statement, John Young, group president of Pfizer Global Established Pharmaceutical business, said adding Hospira “has the potential to fundamentally improve the growth trajectory of the Global Established Pharmaceutical business, vault it into a leadership position in the large and growing off-patent sterile injectables marketplace by combining the specialized talent and capabilities of both companies, including enhanced manufacturing, and advance its goal to be among the world’s most preeminent biosimilars providers.”
Hospira CEO F. Michael Ball added, “The Pfizer-Hospira combination is an excellent strategic fit, presenting a unique opportunity to leverage the complementary strengths of our robust portfolios and rich pipelines.”
The definitive merger agreement is expected to close in the second half of this year.
Most articles on transactions and valuation issues:
Tenet says hospital takeover talks in Connecticut are over
Cardinal Hill Rehabilitation Hospital sold to HealthSouth
North Shore-LIJ, Maimonides Medical Center exploring partnership
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
